Overdose prevention, reduction in opioid and other substance use disorders (SUD), and effective treatment and support for those with SUD are key priorities for the U.S. Food and Drug Administration and personally for me as Commissioner.
Yesterday and today in Washington, D.C., the Reagan-Udall Foundation is facilitating a public meeting of its Independent Expert Panel on food.
The independent expert panel has been charged with evaluating the structure, leadership, authorities, resources and culture of the FDA’s human foods program.
Anyone who has heard Frank Yiannas speak has probably heard his “mango” story. It dates back to his time working for the world’s largest retailer and prior to joining the Food and Drug Administration in 2018 as deputy commissioner for food policy and response. But the story underscores the important role technology can play in current efforts to improve the safety of our food supply and how agency leaders are trying to be more transformative.
During the COVID-19 pandemic, as healthcare systems sought ways to better prevent, treat and manage a previously unseen infection, rapid access to promising novel investigational therapies based on emerging scientific evidence from clinical trials was crucial. This ‘early’ access pathway was via ‘compassionate use’ (CU) programs, which are something I’ve been passionate about for many years.
On Thursday the Reagan-Udall Foundation kicked off a two-day public meeting to solicit input on the big review of FDA’s foods program, and boy, did they get feedback.
On September 21, a two-month independent evaluation of the Food and Drug Administration’s tobacco center commenced amid concern from tobacco control experts that calls to modernize the center were not being taken seriously. In an August 22 letter to the foundation spearheading the evaluation, first reviewed by Filter, two dozen signatories had claimed the discussion lacked a “neutral forum” as well as sufficient “openness, transparency and civil engagement.”
FDA’s Office of Patient Affairs hosts Patient Listening Sessions. These sessions are a resource for the medical product Centers to engage with patients and their advocates. Patient Listening Sessions are one of many ways the patient and advocacy community can share their experiences and perspectives by talking directly with FDA staff.
The Reagan-Udall Foundation, the group tasked with reviewing the FDA’s food safety and tobacco programs, opened up a public portal for anonymous feedback on the FDA’s food safety program on Monday.
For the past several months, the U.S. Food and Drug Administration has been working around the clock with our U.S. government partners, including the U.S. Department of Health and Human Services and the U.S. Department of Agriculture, to expand consumer access to infant formula products, while also ensuring that these products meet the agency’s safety, nutrition and quality standards.
The Reagan-Udall Foundation is looking to collect perspectives and experiences on the Food and Drug Administration’s human foods program through a new “Stakeholder Portal.”
The Reagan-Udall Foundation’s independent expert panel has been charged with evaluating the structure, leadership, authorities, resources, and culture of the FDA’s human foods program.
